{
    "clinical_study": {
        "@rank": "36925", 
        "arm_group": [
            {
                "arm_group_label": "S0597", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be administered with S0597"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The subjects will receive placebo."
            }, 
            {
                "arm_group_label": "Reference", 
                "arm_group_type": "Active Comparator", 
                "description": "The subjects will receive active comparator inhalation powder"
            }
        ], 
        "brief_summary": {
            "textblock": "Sun Pharma Advanced Research company Limited has developed a dry powder inhaler  of compound\n      S0597 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the\n      safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending\n      doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients."
        }, 
        "brief_title": "Pharmacology Study of Sun Pharma Advanced Research Company Limited's S0597", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects  willing to provide informed consent\n\n          -  Male or female subjects aged 18 to 65 years inclusive\n\n          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive\n\n          -  Non-smokers or ex-smokers\n\n        Exclusion Criteria:\n\n          -  Subjects with a supine systolic blood pressure  \u2265160 mmHg and/or a supine diastolic\n             blood pressure \u2265100 mmHg\n\n          -  Subjects who have a significant infection or known inflammatory process on screening\n             or admission.\n\n          -  Subjects who are unlikely to co-operate with the requirements of the study.\n\n          -  Positive serology for infectious disease (hepatitisB or C , HIV) at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041221", 
            "org_study_id": "SPARC_Ltd_ CLR_13_16"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "S0597", 
                    "Placebo", 
                    "Reference"
                ], 
                "description": "The subjects will receive S0597.", 
                "intervention_name": "S0597", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "S0597", 
                    "Placebo", 
                    "Reference"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "The subjects will receive a matching placebo by oral inhalation."
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "pharmacokinetics, pharmacodynamics, asthma", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "state": "Great London", 
                    "zip": "SE1 1YR"
                }, 
                "name": "Quintiles Drug Research Unit at Guy's Hospital, Quintiles Ltd.,"
            }, 
            "investigator": {
                "last_name": "Arpeat Kaviya, MBChB MRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "Study to Access Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Compound S0597 by Oral Inhalation: A Phase I/IIa Observer and Double Blind, Placebo and Active Controlled Parallel and Crossover Study.", 
        "overall_contact": {
            "email": "arpeat.kaviya@quintiles.com", 
            "last_name": "Arpeat Kaviya, MBChB MRCP", 
            "phone": "44 0 20 79107968"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The no of adverse events will be assessed to evaluate the safety and tolerability of compound SO597 in healthy male subjects and asthma patients", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Two (2) Weeks"
            }, 
            {
                "description": "the no of subjects with adverse events will be assessed to evaluate the safety and tolerability of compound SO597 in healthy male subjects and asthma patients", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Two (2) weeks"
            }, 
            {
                "description": "clinically significant changes from baseline in oral body temperature will be  assessed to evaluate the change in vital signs of compound SO597 in healthy male subjects and asthma patients", 
                "measure": "clinically significant changes in oral body temperature", 
                "safety_issue": "Yes", 
                "time_frame": "Two (2) Weeks"
            }, 
            {
                "description": "Clinically significant changes from baseline in pulse rate will be  assessed to evaluate the change in vital signs of compound SO597 in healthy male subjects and asthma patients", 
                "measure": "Clinically significant changes in pulse rate", 
                "safety_issue": "Yes", 
                "time_frame": "Two (2) Weeks"
            }, 
            {
                "description": "Clinically significant changes from baseline in respiratory rate will be  assessed to evaluate the change in vital signs of compound SO597 in healthy male subjects and asthma patients", 
                "measure": "Clinically significant changes in respiratory rate", 
                "safety_issue": "Yes", 
                "time_frame": "Two (2) Weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax will be assessed to evaluate the pharmacokinetics of SO597 in healthy subjects and subjects with asthma.", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Two (2) weeks"
            }, 
            {
                "description": "AUC will be assessed to evaluate the pharmacokinetics of SO597 in healthy subjects and subjects with asthma.", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "Two (2) weeks"
            }, 
            {
                "description": "Clinically significant change in serum cortisol levels will be assessed to evaluate the pharmacodynamics of S0597 in healthy and subjects with mild asthma", 
                "measure": "Clinically significant change in serum cortisol levels", 
                "safety_issue": "No", 
                "time_frame": "Two (2) weeks"
            }, 
            {
                "description": "Clinically significant change in FEV1 will be assessed to evaluate the pharmacodynamics of S0597 in healthy and subjects with mild asthma", 
                "measure": "Clinically significant change in FEV1", 
                "safety_issue": "No", 
                "time_frame": "Two (2) weeks"
            }, 
            {
                "description": "Clinically significant change in FeNo will be assessed to evaluate the pharmacodynamics of S0597 in healthy and subjects with mild asthma", 
                "measure": "Clinically significant change in FeNo", 
                "safety_issue": "No", 
                "time_frame": "Two (2) weeks"
            }
        ], 
        "source": "Sun Pharma Advanced Research Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Pharma Advanced Research Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}